Abstract Number: 85 • 2019 ACR/ARP Annual Meeting
Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
Background/Purpose: The immunoproteasome is a distinct class of proteasome found predominantly in immune effector cells and has been shown to play a distinct role in…Abstract Number: 661 • 2019 ACR/ARP Annual Meeting
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…Abstract Number: 883 • 2019 ACR/ARP Annual Meeting
B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease defined by immune dysregulation, antibody formation, followed by end-organ damage. MyD88 is a central immune…Abstract Number: 1038 • 2019 ACR/ARP Annual Meeting
Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus
Background/Purpose: Cell-bound complement activation products (CB-CAPs) have previously been shown to associate with SLE disease activity, but only a small fraction of total CB-CAPs has…Abstract Number: 1469 • 2019 ACR/ARP Annual Meeting
New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Background/Purpose: The new 2019 SLE EULAR/ACR Classification Criteria for Systemic lupus erythematosus (SLE) have been developed to find a better equilibrium between specificity and sensitivity…Abstract Number: 1596 • 2019 ACR/ARP Annual Meeting
Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients
Background/Purpose: It has been well established that patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease (CVD). Traditional CVD risk…Abstract Number: 1728 • 2019 ACR/ARP Annual Meeting
Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Background/Purpose: Avascular necrosis (AVN) is a serious comorbidity of juvenile systemic lupus erythematosus (jSLE) associated with disability, impaired quality of life, and increased cost of…Abstract Number: 2021 • 2019 ACR/ARP Annual Meeting
Higher Genetic Risk Load in Patients with More Diverse Manifestations in a Korean Systemic Lupus Erythematosus Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with diverse heterogeneous phenotypes. Although many studies of SLE presented estimates of high heritability, impact…Abstract Number: 2282 • 2019 ACR/ARP Annual Meeting
Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population
Background/Purpose: Women of reproductive age with rheumatic diseases are often prescribed teratogenic medications; thus, reproductive counseling is important. A prior study demonstrated improvement in counseling…Abstract Number: 2533 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Increases Low C3 in SLE
Background/Purpose: Hydroxychloroquine is considered an immunomodulatory that does not affect serology. Hydroxychloroquine (HCQ) was recently introduced into Japan. In SLE patients who started hydroxychloroquine, there…Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting
Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…Abstract Number: 2815 • 2019 ACR/ARP Annual Meeting
Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus
Background/Purpose: Studies to date have primarily focused on stimulators that are overexpressed and activate B cells in SLE subjects. Factors that can maintain B cells…Abstract Number: 88 • 2019 ACR/ARP Annual Meeting
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
Background/Purpose: Type I Interferons (IFN) play a key role in the pathogenesis and evolution of various autoimmune diseases. Previous studies have demonstrated that the expression…Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…Abstract Number: 894 • 2019 ACR/ARP Annual Meeting
Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015
Background/Purpose: We evaluated the real-world frequency and severity of flares and associated costs 1 year post diagnosis in a US cohort with newly diagnosed SLE.Methods:…
- « Previous Page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- …
- 150
- Next Page »